Clinical outcomes of sorafenib treatment failure for advanced hepatocellular carcinoma and candidates for regorafenib treatment in real-world practice

Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment

(2017) Sadahisa Ogasawara et al.   INVESTIGATIONAL NEW DRUGS

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

(2017) Jordi Bruix et al.   LANCET

Regional differences in sorafenib-treated patients with hepatocellular carcinoma: GIDEON observational study

(2016) Masatoshi Kudo et al.   LIVER INTERNATIONAL

Hepatocellular Carcinoma From Epidemiology to Prevention: Translating Knowledge into Practice

(2015) Amit G. Singal et al.   Clinical Gastroenterology and Hepatology

EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma

(2015) et al.   JOURNAL OF HEPATOLOGY

Hepatocellular carcinoma: clinical frontiers and perspectives

(2014) Jordi Bruix et al.   GUT

JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan

(2014) Masatoshi Kudo et al.   Liver Cancer

Effect of treatment with branched-chain amino acids during sorafenib therapy for unresectable hepatocellular carcinoma

(2013) Haruhiko Takeda et al.   HEPATOLOGY RESEARCH

Portal hemodynamic effects of sorafenib in patients with advanced hepatocellular carcinoma: a prospective cohort study

(2012) Hisashi Hidaka et al.   JOURNAL OF GASTROENTEROLOGY

Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses

(2012) Jean-Luc Raoul et al.   JOURNAL OF HEPATOLOGY

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

(2012) George D Demetri et al.   LANCET

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

(2012) Axel Grothey et al.   LANCET

Treatment of Advanced Hepatocellular Carcinoma with Emphasis on Hepatic Arterial Infusion Chemotherapy and Molecular Targeted Therapy

(2012) Masatoshi Kudo   Liver Cancer

Application of Radiotherapeutic Strategies in the BCLC-defined Stages of Hepatocellular Carcinoma

(2012) Jihye Cha et al.   Liver Cancer

Management of hepatocellular carcinoma: An update

(2011) Jordi Bruix et al.   HEPATOLOGY

Arterial-phase contrast-enhanced ultrasonography for evaluating anti-angiogenesis treatment: A pilot study

(2011) Keiko Yoshida   WORLD JOURNAL OF GASTROENTEROLOGY

Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion

(2009) Kang Mo Kim et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis

(2008) Kwang-Hyub Han et al.   CANCER

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

(2008) Ann-Lii Cheng et al.   LANCET ONCOLOGY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE

Transcatheter arterial chemoembolization in combination with radiotherapy for unresectable hepatocellular carcinoma: A systematic review and meta-analysis

(2008) Mao-Bin Meng et al.   RADIOTHERAPY AND ONCOLOGY